3 Results for "

TC5619

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "TC5619" in MCE Product Catalog:

Cat. No.: HY-18060
CAS No.: 639489-84-2
Synonyms: TC-5619
Target:  

nAChR

Research Areas:  

Neurological Disease

Bradanicline (TC-5619) is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough .
loading...
    loading...
Cat. No.: HY-18060A
CAS No.: 1111941-90-2
Synonyms: TC-5619 hydrochloride
Target:  

nAChR

Research Areas:  

Neurological Disease

Bradanicline (TC-5619) tosylate is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline hydrochloride exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline hydrochloride possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline hydrochloride requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline hydrochloride is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough .
loading...
    loading...
Cat. No.: HY-18060B
CAS No.: 1111942-11-0
Synonyms: TC-5619 tosylate
Target:  

nAChR

Research Areas:  

Inflammation/Immunology

Bradanicline (TC-5619) tosylate is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline tosylate exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline tosylate possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline tosylate requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline tosylate is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough .
loading...
    loading...